Lenvatinib/pembrolizumab demonstrated efficacy irrespective of tumor burden in advanced renal cell carcinoma in the overall patient population of the phase 3 CLEAR study.
Pembrolizumab plus lenvatinib produced survival outcomes that were consistent with previous findings from the phase 3 LEAP-002 trial along with an extended duration of response.
Lenvatinib plus pembrolizumab, pemetrexed, and carboplatin or cisplatin did not improve treatment outcomes compared with placebo plus pembrolizumab, pemetrexed, and carboplatin or cisplatin when given as first-line therapy in patients with stage IV nonsquamous non–small cell lung cancer.
Lenvatinib in combination with pembrolizumab led to tumor shrinkage and duration of response benefits compared with sunitinib across subgroups of interest in patients with advanced clear cell renal cell carcinoma.